Regular use of aspirin is associated with a lower cardiovascular risk in prostate cancer patients receiving gonadotropin-releasing hormone therapy

Chia Nan University of Pharmacy & Science Institutional Repository > 藥理學院 > 保健營養系(所) > 期刊論文 > Item 310902800/34588

請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/34588

標題:	Regular use of aspirin is associated with a lower cardiovascular risk in prostate cancer patients receiving gonadotropin-releasing hormone therapy
作者:	Chang, Wei-Ting Hong, Chon-Seng Hsieh, Kun-Lin Chen, Yi-Chen Ho, Chung-Han Shih, Jhih-Yuan Kan, Wei-Chih Chen, Zhih-Cherng Lin, You-Cheng
貢獻者:	Chi Mei Hospital Southern Taiwan University of Science & Technology National Cheng Kung University Department of Health and Nutrition, Chia Nan University of Pharmacy & Science Chi Mei Hospital National Cheng Kung University Chi Mei Hospital Department of Health and Nutrition, Chia Nan University of Pharmacy & Science Chi Mei Hospital Chung Hua University Chi Mei Hospital
關鍵字:	agonists mortality disease men testosterone taiwan impact
日期:	2022
上傳時間:	2023-12-11 13:59:20 (UTC+8)
出版者:	FRONTIERS MEDIA SA
摘要:	Gonadotropin-releasing hormone (GnRH) therapy has been known to increase risks of major adverse cardiovascular and cerebrovascular events (MACCEs). Herein, we aim to estimate whether regular use of aspirin attenuates risks of MACCEs in prostate cancer patients receiving GnRHs. Using Taiwanese National Health Insurance Research Database (NHIRD), we identified 7719 patients diagnosed with prostate cancer who were either aspirin-naive, received irregular or regular aspirin from 2008 to 2015. Through a multivariable logistic regression model, we investigated the impact of aspirin on MACCEs. Compared with nonusers and irregular users, most patients receiving regular aspirin were older and had more comorbidities. The crude incidence of one-year MACCEs was lowest in aspirin nonusers but highest in irregular users of aspirin compared with regular users of aspirin (2.65% vs. 4.41% vs. 2.85%, p=0.0099). After adjusting for age, cancer stage and comorbidities, irregular aspirin users had a higher risk of one-year MACCEs (adjusted OR: 1.33; 95% CI: 0.93-1.90, p=0.1139) than aspirin nonusers, but conversely, there was a trend of reducing the risk of MACCEs among those who received regular aspirin (adjusted OR: 0.79; 95% CI: 0.44-1.42, p=0.4256). In the subgroup analysis, there were age- and cancer stage-independent higher risks of MACCEs in patients who took aspirin irregularly compared to those in patients who did not take aspirin. The risks were attenuated in patients receiving regular aspirin. Collectively, regular use of aspirin presented a trend of reducing risks of MACCEs in prostate cancer patients receiving GnRHs. However, irregular use of aspirin diminished the benefits.
關聯:	FRONTIERS IN ONCOLOGY, v.12, n.CB2, pp.CC2, pp.-2874,
顯示於類別:	[保健營養系(所) ] 期刊論文

文件中的檔案:

檔案	描述	大小	格式	瀏覽次數
fonc.2022.952370.pdf		668Kb	Adobe PDF	45	檢視/開啟
index.html		0Kb	HTML	290	檢視/開啟

在CNU IR中所有的資料項目都受到原著作權保護.

TAIR相關文章

資料載入中.....